Pelican-Cancer-Foundation-logos
Donate Now
Search
Pelican-Cancer-Foundation-logos

Dedicated to helping patients with bowel and liver cancer live well for longer

Donate Now
Search
  • Home
  • About us
    • About us
    • What we do
      • Our achievements
      • The Future
    • Who we are
      • Trustees
      • Our Team
      • Patrons
      • Annual Accounts
    • Partnerships
    • Vacancies
    • News
  • Education
    • Pelican OReCO
      • OReCO On-line Resources
      • OReCO Partners & Sponsors
      • Pelican OReCO Workshops
    • Pelican IMPACT
      • IMPACT – Completion & Evaluation
      • Workshops
      • IMPACT – Online resources
      • IMPACT – Partners and Sponsors
    • SPECC
      • SPECC – Completion & Evaluation
      • Workshops
      • SPECC – Online resources
      • SPECC – Partners and Sponsors
    • LOREC
    • TIPTOP
      • Workshops
      • TIPTOP – Online resources
      • Bob’s story (prostate cancer)
      • Andrew’s story (prostate cancer)
      • Alan’s story (prostate cancer)
      • Raymond’s story (prostate cancer)
    • LARS
    • Sponsors
      • Become a sponsor
    • Request a course or topic
    • Give us feedback
    • Previous courses
  • Films
  • Research
    • MERCURY 3
    • Research strategy
    • Bowel cancer research
      • POLARS
      • MERCURY 2 (Low Rectal Cancer Study)
      • Deferral of surgery study
      • TATME
      • IMPRESS
      • TRIGGER
      • Papers of interest
      • Timing of surgery
      • AMSOEC
      • MINSTREL
      • Completed research
        • Perineal wound healing registry
        • Beyond TME
        • Validation of the LARS score
        • MARVEL: Evaluation of EMVI positive rectal cancer
        • FLEX
        • TME Physical Simulation Model
        • Total Mesorectal Excision (TME)
        • MERCURY research programme
    • Liver cancer research
      • Completed research
        • EORTC studies
      • SERENADE
      • Papers of interest
    • Peritoneal malignancy research
      • Colorectal Peritoneal Malignancy Database
      • Pseudomyxoma Pathology Atlas
    • Previous Research Areas
      • Prostate Cancer Research
        • Prostate cancer
        • Focal therapy and HIFU research
        • MRI research for prostate cancer
        • Prostate cancer colloquiums
        • FORECAST
        • Trachtomap
        • Papers of interest
      • Bladder cancer research
        • Bladder cancer
        • Papers of interest
    • Peer reviewers
    • Clinical trials
    • Information for research applicants
      • Peer Review Panel Terms of Reference
      • Research Review Panel
      • Research Grant Application Guidance Notes
      • Terms and conditions of grants
      • Animals in medical research
      • Research costs
    • Surgical videos
  • For Patients
    • Patient stories
      • Anthony’s story (bowel cancer)
      • Elena’s story (bowel cancer)
      • Terry’s story (liver cancer)
      • Derrick’s story (liver cancer)
      • Alex’s story (colorectal cancer)
      • Cheryll’s story (rectal cancer)
      • Eileen’s story
      • Richard’s story – irrigation
      • Tom’s story – complete response
      • Advanced metastatic bowel cancer
    • What is an MDT?
      • What an MRI reveals
      • Reporting cancer outcomes
    • Bowel cancer
      • Our bowel cancer team
      • About bowel cancer treatment – TME
      • April – Bowel Cancer Awareness Month
      • Low rectal cancer
      • Complete response to chemoradiotherapy in rectal cancer
      • Frequently asked questions about bowel cancer
      • Irrigation for colostomies
      • A patient’s advice
      • Symptom checker
      • Bowel cancer – useful contacts
    • Liver cancer
      • Our liver cancer team
      • About liver cancer treatment
      • Interventional radiology
      • Liver cancer – frequently asked questions
      • Carcinoid and neuroendocrine tumours
      • Liver cancer – want to read more?
    • Pseudomyxoma peritonei
    • Getting a second opinion
    • Clinical trials
      • Current clinical trials
    • Tell us your story
    • Still got questions about cancer?
    • Links
  • Support us
    • Make a donation
      • Make a donation
      • Shares
      • In memory
    • Fundraise for us
      • Our fundraisers
      • Fundraising ideas
      • Fundraising challenges
      • Fundraising resources
    • Leave a Gift in your Will
    • Become a Corporate Partner
    • Trusts, Foundations & Philanthropy
    • Tell us your story
  • Contact us

Papers of interest

Below Pelican has listed a selection of papers that reflect the areas of research that we have been involved in and continue to support. Where possible the links to the abstracts are included for further information.

Recent advances in Intravesical therapy for non muscle invasive bladder cancer. Mostafid A H. In Nilsson W.E. ed, Bladder Cancer: Etymology, Diagnosis and Treatment, 1st edn, Chapt 3. Ohio: Nova Science Publishers, 2010.

Hexylaminolevulinate (Hexvix®)-guided fluorescence cystoscopy in the diagnosis and follow up of patients with non-muscle invasive bladder cancer: review of the evidence and recommendations from a European expert panel.J.A.Witjes, J. Palou, D. Jacqmin, F. Sofras, P. Malmström, C. Riedl, D. Jocham, G. Conti, F. Montorsi, H.C. Arentsen, D. Zaak, A.H Mostafid, M. Babjuk. Eur Urol. 2010;57(4):607-614.

Is It Time To Re-Design The Haematuria Clinic? Mostafid H, Persad R, Kockelbergh R, Fawcett D. B J Urol. 2010;105(5):585-8.

The role of hexylaminolaevulinate in the diagnosis and follow-up of non-muscle-invasive bladder cancer. Bunce C, Ayres BE, Griffiths TR, Mostafid H, Kelly J, Persad R, Kockelbergh R. BJU Int. 2010 Feb;105 Suppl 2:2-7.

Management of Bladder cancer Mostafid H. Trends in Urology 2009; 14:10-15.

Improved detection and reduced early recurrence of non-muscle-invasive bladder cancer using hexaminolaevulinate fluorescence cystoscopy: results of a multicentre prospective randomized study (PC B305). Mostafid H, Bunce C. Br J Urol. 2009; 104: 889-890.

Immediate Postoperative Instillation of Intravesical Mitomycin in Theatre: Outcome and Effect on Recurrence of Non Muscle-Invasive Bladder Cancer. Biers S, Moon DA , Mostafid H. Curr Urol 2009;3:72-75.

Electromotive drug administration of local anaesthesia for biopsy and cystodiathermy of recurrent low grade bladder tumours.Biers S, Mostafid AH. Curr Urol 2009;3:15-18.

Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer. Horvath A, Mostafid H. Br J Urol 2009;103:726-769.

The use of the NMP 22 BladderChek test for bladder cancer to optimise investigations in a one-stop haematuria clinic.Bott S, Chanawani M, Mostafid H. BJMSU 2008;1:126-130.

Immediate post operative administration of intravesical Mitomycin in theatre for non-muscle invasive bladder cancer.Horvath A , Chanawani M, Mostafid A H . Br J Urol Atlas of Surgery, 2008

Differential diagnosis of isolated iliac lymphadenopathy following Bacillus Calmette-Guerin treatment for high-risk superficial bladder cancer. Biers S, Di Marco A, Mostafid A H, Int Urol Nephrol2007;39(4):1039-41.

The management of hydronephrosis in patients undergoing TURBT Thiruchevlam N, Ubhayakar G, Mostafid H. Int Urol Nephrol 2006; 38(3-4): 483-6. (http://www.ncbi.nlm.nih.gov/pubmed/17115297)

Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer. Mostafid AH, Rajkumar RG, Stewart AB, Singh R. Br J Urol 2006 Mar; 97(3):509-12.

Stay in touch

Sign up to hear from us
Donate Now

© 2023 Pelican Cancer Foundation - all rights reserved

  Registered Charity Number: 1141911 -  Privacy Policy